Sonidegib (INN; also known as LDE225 and erismodegib; trade name Odomzo) is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis.

Property Value
dbo:abstract
  • Sonidegib (INN; also known as LDE225 and erismodegib; trade name Odomzo) is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis. (en)
dbo:alternativeName
  • Odomzo (en)
dbo:chEBI
  • 90863
dbo:fdaUniiCode
  • 0RLU3VTK5M
dbo:kegg
  • D10119
dbo:pubchem
  • 24775005
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2019-06-21 14:41:42Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 41957427 (xsd:integer)
dbo:wikiPageLength
  • 11911 (xsd:integer)
dbo:wikiPageModified
  • 2019-06-20 19:25:27Z (xsd:date)
dbo:wikiPageOutDegree
  • 29 (xsd:integer)
dbo:wikiPageRevisionID
  • 902719677 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Sonidegib (INN; also known as LDE225 and erismodegib; trade name Odomzo) is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis. (en)
rdfs:label
  • Sonidegib (en)
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of